Praxis Precision Medicines (NASDAQ:PRAX – Get Rating)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have a $16.00 price target on the stock. Separately, William Blair downgraded shares of Praxis Precision Medicines from an “outperform” rating to a “market perform” rating in a […]

Related Keywords

Marcio Souza , William Blair , Nasdaq , Vanguard Group Inc , Securities Exchange Commission , Health Sciences , Praxis Precision Medicines Inc , Blackrock Inc , Praxis Precision Medicines , Get Rating , Precision Medicines , Praxis Precision , Director Dean , Exchange Commission , Street Corp , Praxis Precision Medicines Daily , Nasdaq Prax , Aprax , Medical , Reiterated Rating , Hc Wainwright ,